Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hypertensive heart failure (HHF) presents a significant clinical challenge due to its high incidence and poor patient outcomes.
• Effective therapeutic strategies for HHF remain an area of active research and clinical need.

Purpose of the Study:

• To evaluate the efficacy and safety of Vericiguat in patients diagnosed with hypertensive heart failure (HHF).
• To investigate the correlation between C-reactive protein (CRP) levels and the prognosis of patients with HHF.

Main Methods:

• A study involving 110 HHF patients randomized into Placebo and Vericiguat groups.
• Cardiac function assessed via echocardiography and the 6-minute walk test (6MWT).
• Biomarkers including NT-proBNP, cTnI, ET-1, NO, and CRP were measured.

Main Results:

• Vericiguat treatment led to improved cardiac function, evidenced by reduced LVESD/LVEDD, increased LVEF, and enhanced 6MWT performance.
• Significant improvements in NT-proBNP, cTnI, ET-1, NO, and CRP levels were observed in the Vericiguat group.
• The Vericiguat group showed a higher total effective rate (92.7%) versus placebo (76.4%), with comparable adverse event rates.
• Elevated baseline CRP levels were associated with a higher proportion of patients experiencing poor prognosis and no improvement in cardiac function, identifying CRP as an independent risk factor.

Conclusions:

• Vericiguat demonstrates both safety and efficacy in enhancing cardiac function for patients suffering from hypertensive heart failure (HHF).
• Baseline C-reactive protein (CRP) levels serve as a crucial indicator for predicting prognosis in HHF patients.